Education
Case Report Podcast Edward D. Kim, MD, reviews a patient case from his clinical practice, addressing how to incorporate the application of topical testosterone into a daily hygiene routine. Discussion includes history, diagnosis, management, treatment, and follow-up. This educational activity is eligible for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ through April 30, 2014.Case Report Podcast Allen D. Seftel, MD, describes a challenging case from his practice, focusing on differences between testosterone formulations for a patient with adherence concerns. Discussion includes history, diagnosis, management, treatment, and follow-up. This educational activity is eligible for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ through March 31, 2014.
Symposium at AUA Attend Integrating Urologic and Primary Care Perspectives: Recognizing Early Signals to Halt the Cycle of Hypogonadism, Erectile Dysfunction, and Cardiometabolic Disease, a free CME-certified dinner symposium to be held May 4, 2013, at the San Diego Convention Center in conjunction with AUA2013. Faculty Jennifer R. Berman, MD; Culley C. Carson III, MD; and Martin M. Miner, MD, will examine strategies to improve adherence and satisfaction with PDE5 inhibitor therapy and testosterone therapy and focus on the concomitant management of ED, BPH/LUTS, CVD, and hypogonadism to define how the management of these conditions may improve cardiometabolic parameters and overall cardiovascular health.
Breaking News Experts respond to interview questions on managing men's health in this interactive video clinical opinion series featuring TU Distinguished Faculty Abraham Morgentaler, MD (Chairperson), and Adrian S. Dobs, MD, MHS. This educational activity is eligible for a maximum of 1.5 AMA PRA Category 1 Credit(s)™ through December 28, 2013.
Newsletter Graham Jackson, MB(Hons), and Wayne J.G. Hellstrom, MD, discuss the need for clinicians to educate patients about appropriate and inappropriate sources of health information and medications, particularly testosterone. This educational activity is eligible for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ through December 28, 2013.
TU Journal Adrian S. Dobs, MD, MHS, and Abraham Morgentaler, MD, examine the current evidence suggesting potential additional beneficial effects of testosterone therapy on cardiometabolic disease and male osteoporosis and discuss the simultaneous treatment of hypogonadism and these related conditions. This educational activity is eligible for a maximum of 1.5 AMA PRA Category 1 Credit(s)™ through December 28, 2013.
Symposium at AAFP View the video presentations of Case in Point—Shifting Treatment Paradigms: Synergistic Management of BPH/LUTS, Hypogonadism, and ED, the TU symposium held in conjunction with the 2012 American Academy of Family Physicians Scientific Assembly. Culley C. Carson III, MD, served as Chairperson, with faculty Kevin T. McVary, MD, and Martin M. Miner, MD. This educational activity is approved by the AAFP for up to 1.25 Prescribed credit(s) and is eligible for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ through December 17, 2013.Breaking News Experts respond to interview questions on managing men's health in this interactive video clinical opinion series featuring TU Distinguished Faculty Culley C. Carson III, MD (Chairperson); Kevin T. McVary, MD; and Martin M. Miner, MD. This educational activity is eligible for a maximum of 1.5 AMA PRA Category 1 Credit(s)™ through November 30, 2013.
Doctor Is In—Parts 1-5 Participate in the Doctor Is In case studies, which follow patients with hypogonadism over the course of their office visits. Patient histories, lab results, and office notes are followed by multiple-choice questions to elicit the diagnoses and treatment plans. Faculty are Graham Jackson, MB(Hons); T. Hugh Jones, MD, MB, ChB, BSc; and Martin M. Miner, MD. This educational activity is eligible for a maximum of 2.5 AMA PRA Category 1 Credit(s)™ through September 30, 2013. (Parts 1-4 expire sooner; see CME Information.)
Symposium at AUA Read the proceedings of the TU symposium Testosterone Therapy and Prostate Health: Examining Barriers to Treatment of Hypogonadism, held during AUA2012. Participant feedback named it "Best program… at AUA." Culley C. Carson III, MD, served as Chairperson, with faculty Mohit Khera, MD, MBA, MPH; Abraham Morgentaler, MD; and Jacob Rajfer, MD. This educational activity is eligible for a maximum of 1.5 AMA PRA Category 1 Credit(s)™ through August 31, 2013.
Doctor on Call Podcast Culley C. Carson III, MD; Kevin T. McVary, MD; and Martin M. Miner, MD, have a conversation about their clinical experience with and the latest evidence on the diagnosis and management of hypogonadism. This educational activity is eligible for a maximum of 0.5 AMA PRA Category 1 Credit(s)™ through August 31, 2013.
Slide Library Access comprehensive slide sets on hypogonadism, including sets for specialties, updated with emerging clinical data and innovative therapies, for healthcare professionals creating presentations. Download more than 200 slides FOR FREE.
Testosterone Therapy and Prostate Health: Examining Barriers to Treatment of Hypogonadism Access the program guide from the CME-certified symposium held in conjunction with the American Urological Association's 2012 Annual Meeting. The faculty are Culley C. Carson III, MD (Chairperson); Mohit Khera, MD, MBA, MPH; Abraham Morgentaler, MD; and Jacob Rajfer, MD.
Hypogonadism and Cardiometabolic Disease: Defining the Relationship View presentations from the CME-certified symposium exploring the relationship between hypogonadism and cardiovascular disease held in conjunction with the American College of Physicians annual meeting, Internal Medicine 2012. Wayne J.G. Hellstrom, MD, serves as Chairperson, and the faculty are Adrian S. Dobs, MD, MHS, and Martin M. Miner, MD.
Newsletter Richard Sadovsky, MD, and Ajay Nehra, MD, discuss managing hypogonadism in patients who are HIV positive. Although this activity is no longer eligible for CME credit, it remains available on this website as an educational resource.
KOL Video Debate Four multidisciplinary key opinion leaders debate cutting-edge issues in 6 videos, each highlighting a different aspect of hypogonadism management. Martin M. Miner, MD (primary care), serves as Chairperson, and the faculty are Adrian S. Dobs, MD, MHS (endocrinology); Robert A. Kloner, MD, PhD (cardiology); and Abraham Morgentaler, MD (urology). Although this activity is no longer eligible for CME credit, it remains available on this website as an educational resource.
Newsletter Adrian S. Dobs, MD, MHS, and John E. Morley, MB, BCh, discuss the relationship between hypogonadism and osteoporosis. Although this activity is no longer eligible for CME credit, it remains available on this website as an educational resource.
Case Study This 3-part case study follows a patient over the course of 9 months of office visits. A patient history, lab results, and office notes are followed by multiple-choice questions to elicit the diagnosis and treatment plan. The faculty are Robert A. Feldman, MD, and Joel M. Kaufman, MD. Although this activity is no longer eligible for CME credit, it remains available on this website as an educational resource.
ENDO Conference Courier Report The impact of hypogonadism on men's overall health and well-being was one of the state-of-the-art topics at the Endocrine Society's 93rd Annual Meeting and Expo. The faculty are Adrian S. Dobs, MD, MHS, and Christina Wang, MD. Although this activity is no longer eligible for CME credit, it remains available on this website as an educational resource.
AUA Conference Courier Report Hypogonadism and its impact on men's health was one of the state-of-the-art topics at the 2011 annual meeting of the American Urological Association. Martin M. Miner, MD, and Ajay Nehra, MD, are faculty. Although this activity is no longer eligible for CME credit, it remains available on this website as an educational resource.
Newsletter Abdulmaged M. Traish, MBA, PhD, and Andre T. Guay, MD, examine the interrelationship of type 2 diabetes, insulin resistance, and hypogonadism, discuss the pathophysiologic link, and offer treatment strategies. Although this activity is no longer eligible for CME credit, it remains available on this website as an educational resource.
Newsletter Glenn R. Cunningham, MD, and Robert S. Tan, MD, MBA, survey the range of testosterone formulations, focusing on the gels currently available and those in development, and offer clinical tips for optimizing safety, efficacy, and adherence. Although this activity is no longer eligible for CME credit, it remains available on this website as an educational resource.
Newsletter Ronald S. Swerdloff, MD, and Wayne J.G. Hellstrom, MD, respond to public confusion of anabolic-androgenic steroid abuse and testosterone therapy. Although this activity is no longer eligible for CME credit, it remains available on this website as an educational resource.Case Study This 3-part case study follows a patient over the course of 9 months of office visits. A patient history, lab results, and office notes are followed by multiple-choice questions to elicit the diagnosis and treatment plan. Although this activity is no longer eligible for CME credit, it remains available on this website as an educational resource.
Newsletter Ronald S. Swerdloff, MD, and Adrian S. Dobs, MD, MHS, evaluate the research exploring the association between testosterone and cardiovascular disease. Although this activity is no longer eligible for CME credit, it remains available on this website as an educational resource.
ENDO Conference Courier Highlights The treatment of hypogonadism was one of the state-of-the-art topics at the 2010 annual meeting of the Endocrine Society.
AUA Conference Courier Highlights Hypogonadism and its impact on men’s health was one of the state-of-the-art topics at the 2010 annual meeting of the American Urological Association.
Downloadable TU Toolkit Four clinical tools support hypogonadism diagnosis, management, and patient care, including tips on raising patient awareness about hypogonadism.
Town Hall Forum Proceedings TestosteroneUpdate Distinguished Faculty convened to discuss cutting-edge information concerning the diagnosis and treatment of hypogonadism, with the goal of increasing awareness about this underrecognized and undertreated condition. Although this activity is no longer eligible for CME credit, it remains available on this website as an educational resource.American Urological Association Conference Courier Highlights Report on Hypogonadism The treatment of hypogonadism was one of the state-of-the-art topics at the 2009 annual meeting of the American Urological Association.Endocrine Society Conference Courier Highlights Report on Hypogonadism The treatment of hypogonadism was one of the state-of-the-art topics at the 2009 annual meeting of the Endocrine Society.
Frequently Asked Questions This downloadable reference guide answers commonly asked questions about the diagnosis, management, and treatment of hypogonadism. Topics include comorbidities, efficacy and safety of testosterone therapy, and tips for optimizing long-term persistence with testosterone therapy and treatment success.
Highlights From Disease State Theater Experts from the fields of endocrinology, primary care, and urology presented at the 2008 American Urological Association and Endocrine Society annual meetings on treatment of hypogonadism in men. The proceedings from these meetings review the current data on hypogonadism and offer recommendations that can be incorporated into your clinical practice.
Disease State Theater Podcast View the presentations from the 2008 annual meetings of the American Urological Association and the Endocrine Society. 
Multidisciplinary Insights Into the Assessment, Diagnosis, and Management of Hypogonadism Experts from the fields of endocrinology, primary care, and urology participated in a roundtable discussion focusing on the diagnosis and treatment of hypogonadism in men.
Proceedings From the TU 1st Annual Conference on Improving Clinical Outcomes in Hypogonadism Physicians at the forefront of treatment and research presented and discussed treatment considerations in the management of hypogonadism.
Emerging Evidence and Future Directions in Treating Hypogonadism Four to five million American men are affected by hypogonadism. There are several challenges concerning hypogonadism, from the clinical diagnosis to the safety of testosterone therapy. It is important for clinicians to have an understanding of male hypogonadism and how to apply clinical guidelines in their practice to improve patient outcomes. This monograph examines issues facing physicians who manage patients with hypogonadism, offering information to help make informed treatment decisions. Co-authors are Adrian S. Dobs, MD, MHS, and Frances J. Hayes, MD.
Optimizing Patient Safety in the Management of Hypogonadism This satellite symposium was presented at the 16th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists.
Bridging the Treatment Gaps in the Management of Hypogonadism At their 2007 meeting, TU Distinguished Faculty addressed issues facing clinicians who treat men with hypogonadism. Where evidence was lacking, they offered considerations to help clinicians make informed treatment decisions. This clinical statement paper was developed based on the discussions and interaction at this meeting.
